05:50 AM EDT, 04/08/2024 (MT Newswires) -- Black Diamond Therapeutics ( BDTX ) said Sunday that preclinical data showed that BDTX-1535 potentially inhibits non-classical mutations in non-small cell lung cancer patients.

Real-world data showed non-classical mutations were present in 20% to 30% of subject patients with non-small cell lung cancer, and that BDTX-1535 has the potential to address a broader range of mutations versus existing therapies, the company said.

Preclinical data showed that the drug potently inhibits more than 50 non-classical epidermal growth factor receptor mutations, it added.